Thank you to the 2016 BIO International Convention Program Committee (pdf) for their devoted efforts in creating a world-class education for BIO 2016. The Committee meets on a continuing basis to determine the most cutting edge topics and speakers, and is led by three outstanding Program Chairs and supported by numerous individuals in all sectors of biotechnology.
Jeff is on the New Ventures team at Johnson & Johnson Innovation, California. Jeff joined the Johnson & Johnson Family of Companies in February 2011 and helped to establish the California Innovation Center. He also worked for 18 months making and managing venture investments for Johnson & Johnson. A licensed physician, he has over two decades of diversified healthcare and business experience: as a senior operating executive, business development professional, venture investor, entrepreneur, and clinician. He began his business career as a management consultant at McKinsey & Company. He later served as a healthcare research analyst at JP Morgan Hambrecht & Quist. As an entrepreneur, he ran corporate development and operations for WIDCOMM, a technology company acquired by Broadcom, and served as CFO & CBO for Vela Pharmaceuticals, a venture-backed drug development company. From 2006 to 2010 he was a Principal & Kauffman Fellow at Scale Venture Partners, a venture fund with over $1B under management.
He graduated Phi Beta Kappa in Biology from Harvard College and earned an M.D. from Harvard Medical School, where he was a Rotary International Ambassadorial Scholar. He completed his medical-psychiatric internship and psychiatry residency at UCLA’s Neuropsychiatric Institute and served as program chief resident. Afterwards, he was awarded and completed a clinical neuropharmacology fellowship focusing on the care of treatment-refractory patients.
Simone serves as Editor of BioCentury's translational publication, Biocentury Innovations. Prior to joining BioCentury in 2013, Simone worked as a translational scientist in biotech, including nine years in preclinical drug development at Nektar Therapeutics. Before industry, Simone carried out research at the Weizmann Institute of Science, after completing a post-doc at the University of California, San Francisco (UCSF). Simone also serves as an advisor on the translational SPARK program at Stanford University and the CTSI Catalyst program at UCSF. She is a Fulbright scholar, and holds a Ph.D. in molecular pharmacology from the Weizmann, and an M.A. and B.A. in pharmacology from Cambridge University.
John R. A. McSherry is a Life Science and Diagnostic Executive that resides with his wife Cynthia in the Bay Area. He received his degrees in Economics and Political Science from the University of Richmond, Virginia before eventually working in increasing roles of responsibility with F.Hoffmann-LaRoche, Genentech, Bio-Rad Laboratories, Baxter Healthcare International and Quintiles Transnational. After a twenty-year career in multiple Life Science and Diagnostic functions and as a patient advocate inside the industry, he is now focused and engaged in Digital Health and Precision Medicine initiatives. McSherry has served BIO since 2013 and been a Member of the California Life Science Association (previously BayBio) since 2006. He has written and consulted on numerous aspects of PharmacoEconomics, guiding optimal healthcare resource allocation, in a standardized and scientifically grounded manner. Most recently he published a white paper for Quintiles Transnational entitled Changing the fixed-to-variable ratio in dynamic commercial solutions.